Literature DB >> 17548584

Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis.

Carole Peyssonnaux1, Pilar Cejudo-Martin, Andrew Doedens, Annelies S Zinkernagel, Randall S Johnson, Victor Nizet.   

Abstract

Sepsis, the leading cause of death in intensive care units, reflects a detrimental host response to infection in which bacteria or LPS act as potent activators of immune cells, including monocytes and macrophages. In this report, we show that LPS raises the level of the transcriptional regulator hypoxia-inducible factor-1alpha (HIF-1alpha) in macrophages, increasing HIF-1alpha and decreasing prolyl hydroxylase mRNA production in a TLR4-dependent fashion. Using murine conditional gene targeting of HIF-1alpha in the myeloid lineage, we demonstrate that HIF-1alpha is a critical determinant of the sepsis phenotype. HIF-1alpha promotes the production of inflammatory cytokines, including TNF-alpha, IL-1, IL-4, IL-6, and IL-12, that reach harmful levels in the host during early sepsis. HIF-1alpha deletion in macrophages is protective against LPS-induced mortality and blocks the development of clinical markers including hypotension and hypothermia. Inhibition of HIF-1alpha activity may thus represent a novel therapeutic target for LPS-induced sepsis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548584     DOI: 10.4049/jimmunol.178.12.7516

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  198 in total

Review 1.  Molecular oxygen sensing: implications for visceral surgery.

Authors:  Judit Kiss; Johanna Kirchberg; Martin Schneider
Journal:  Langenbecks Arch Surg       Date:  2012-03-07       Impact factor: 3.445

2.  IFN-γ attenuates hypoxia-inducible factor (HIF) activity in intestinal epithelial cells through transcriptional repression of HIF-1β.

Authors:  Louise E Glover; Karina Irizarry; Melanie Scully; Eric L Campbell; Brittelle E Bowers; Carol M Aherne; Douglas J Kominsky; Christopher F MacManus; Sean P Colgan
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

Review 3.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease.

Authors:  Nels Olson; Albert van der Vliet
Journal:  Nitric Oxide       Date:  2011-01-01       Impact factor: 4.427

4.  Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.

Authors:  Hongxia Z Imtiyaz; Emily P Williams; Michele M Hickey; Shetal A Patel; Amy C Durham; Li-Jun Yuan; Rachel Hammond; Phyllis A Gimotty; Brian Keith; M Celeste Simon
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

5.  Autocrine effect of vascular endothelial growth factor-A is essential for mitochondrial function in brown adipocytes.

Authors:  Kiana Mahdaviani; David Chess; Yuanyuan Wu; Orian Shirihai; Tamar R Aprahamian
Journal:  Metabolism       Date:  2015-09-25       Impact factor: 8.694

6.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

Review 7.  Metabolism of inflammation limited by AMPK and pseudo-starvation.

Authors:  Luke A J O'Neill; D Grahame Hardie
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

8.  A novel PINK1- and PARK2-dependent protective neuroimmune pathway in lethal sepsis.

Authors:  Rui Kang; Ling Zeng; Yangchun Xie; Zhengwen Yan; Borong Zhou; Lizhi Cao; Daniel J Klionsky; Kevin J Tracey; Jianhua Li; Haichao Wang; Timothy R Billiar; Jianxin Jiang; Daolin Tang
Journal:  Autophagy       Date:  2016-10-18       Impact factor: 16.016

9.  Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor.

Authors:  So Young Kim; Yong Jun Choi; Sun Myung Joung; Byung Ho Lee; Yi-Sook Jung; Joo Young Lee
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

Review 10.  HIF1α and metabolic reprogramming in inflammation.

Authors:  Sarah E Corcoran; Luke A J O'Neill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.